Groves Ashley M, Win Thida, Screaton Nicholas J, Berovic Marko, Endozo Raymondo, Booth Helen, Kayani Irfan, Menezes Leon J, Dickson John C, Ell Peter J
Institute of Nuclear Medicine, University College London, London, United Kingdom.
J Nucl Med. 2009 Apr;50(4):538-45. doi: 10.2967/jnumed.108.057901. Epub 2009 Mar 16.
The purpose of this study was to evaluate integrated (18)F-FDG PET/CT in patients with idiopathic pulmonary fibrosis (IPF) and diffuse parenchymal lung disease (DPLD).
Thirty-six consecutive patients (31 men and 5 women; mean age +/- SD, 68.7 +/- 9.4 y) with IPF (n = 18) or other forms of DPLD (n = 18) were recruited for PET/CT and high-resolution CT (HRCT), acquired on the same instrument. The maximal pulmonary (18)F-FDG metabolism was measured as a standardized uptake value (SUV(max)). At this site, the predominant lung parenchyma HRCT pattern was defined for each patient: ground-glass or reticulation/honeycombing. Patients underwent a global health assessment and pulmonary function tests.
Raised pulmonary (18)F-FDG metabolism in 36 of 36 patients was observed. The parenchymal pattern on HRCT at the site of maximal (18)F-FDG metabolism was predominantly ground-glass (7/36), reticulation/honeycombing (26/36), and mixed (3/36). The mean SUV(max) in patients with ground-glass and mixed patterns was 2.0 +/- 0.4, and in reticulation/honeycombing it was 3.0 +/- 1.0 (Mann-Whitney U test, P = 0.007). The mean SUV(max) in patients with IPF was 2.9 +/- 1.1, and in other DPLD it was 2.7 +/- 0.9 (Mann-Whitney U test, P = 0.862). The mean mediastinal lymph node SUV(max) (2.7 +/- 1.3) correlated with pulmonary SUV(max) (r = 0.63, P < 0.001). Pulmonary (18)F-FDG uptake correlated with the global health score (r = 0.50, P = 0.004), forced vital capacity (r = 0.41, P = 0.014), and transfer factor (r = 0.37, P = 0.042).
Increased pulmonary (18)F-FDG metabolism in all patients with IPF and other forms of DPLD was observed. Pulmonary (18)F-FDG uptake predicts measurements of health and lung physiology in these patients. (18)F-FDG metabolism was higher when the site of maximal uptake corresponded to areas of reticulation/honeycomb on HRCT than to those with ground-glass patterns.
本研究的目的是评估[18F]氟代脱氧葡萄糖([18F]FDG)PET/CT在特发性肺纤维化(IPF)和弥漫性实质性肺疾病(DPLD)患者中的应用。
连续纳入36例患者(31例男性和5例女性;平均年龄±标准差,68.7±9.4岁),其中IPF患者18例,其他形式的DPLD患者18例,均接受PET/CT和高分辨率CT(HRCT)检查,且两种检查使用同一台仪器。测量肺部最大[18F]FDG代谢作为标准化摄取值(SUVmax)。在该部位,为每位患者确定主要的肺实质HRCT模式:磨玻璃影或网状/蜂窝状影。患者接受全面健康评估和肺功能测试。
36例患者均观察到肺部[18F]FDG代谢升高。HRCT上最大[18F]FDG代谢部位的实质模式主要为磨玻璃影(7/36)、网状/蜂窝状影(26/36)和混合模式(3/36)。磨玻璃影和混合模式患者的平均SUVmax为2.0±0.4,网状/蜂窝状影患者的平均SUVmax为3.0±1.0(Mann-Whitney U检验,P = 0.007)。IPF患者的平均SUVmax为2.9±1.1,其他DPLD患者的平均SUVmax为2.7±0.9(Mann-Whitney U检验,P = 0.862)。平均纵隔淋巴结SUVmax(2.7±1.3)与肺部SUVmax相关(r = 0.63,P < 0.001)。肺部[18F]FDG摄取与全面健康评分(r = 0.50,P = 0.004)、用力肺活量(r = 0.41,P = 0.014)和转移因子(r = 0.37,P = 0.042)相关。
观察到所有IPF和其他形式DPLD患者的肺部[18F]FDG代谢均增加。肺部[18F]FDG摄取可预测这些患者的健康状况和肺生理指标。当最大摄取部位在HRCT上对应网状/蜂窝状区域而非磨玻璃影区域时,[18F]FDG代谢更高。